Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADB-102
- Development stage
- Preclinical
- Lead developer
- Adolore Biotherapeutics
- Modality
- Gene Therapies
- Administration
- Intraarticular
01
Overview
ADB-102 is a novel, non-opioid gene therapy in preclinical development for the treatment of chronic pain associated with knee osteoarthritis. Developed by Adolore BioTherapeutics, it utilizes a replication-defective herpes simplex virus (rdHSV) vector to deliver a modified carbonic anhydrase 8 (CA8*) gene locally to peripheral sensory nerve fibers within the knee joint. The therapy aims to reduce pain by modulating neuronal excitability through activation of Kv7 voltage-gated potassium channels, addressing neuropathic, inflammatory, and nociceptive pain mechanisms. Supported by NIH HEAL grant funding and validated in preclinical models, ADB-102 is being advanced toward IND filing and first-in-human clinical studies[2][3][5][7].
02
Targets
IP3R1 (Inositol 1,4,5-trisphosphate receptor 1)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))CA8 (Carbonic anhydrase VIII)
Beyond the preview
Go deeper on ADB-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADB-102.